If AVITA Medical was sitting on your watchlist instead of in your account, the recent move probably hurts to look at. Holding AVITA Medical from the start of the year would have returned 337.5%, including dividends. That jump landed after a period when analysts were split between a Medicare recovery story and worries about reimbursement pressure and product concentration. If you rewind to 1 January 2026, how much weight would you really have put on Medicare resolution and trauma expansion actually resetting this business?
The easy part of this move is behind AVITA Medical. Zero in on 29 high quality undervalued stocks for companies trading below our estimates.
The Argument You Would Have Had To Settle On AVITA Medical
The shares cost US$3.45 at the start of the period, and AVITA Medical sat between two very different stories investors had to weigh.
The bullish view saw a Fair Value of US$8.26, essentially the price implied if Medicare reimbursement recovered and trauma expansion lifted usage as assumed. Supporters leaned on expectations for 42.5% revenue growth and profit margins climbing to 35.8% over three years.
The cautious side worked off a Fair Value of US$3, a lower implied outcome built around ongoing reimbursement pressure. This narrative focused on the risk that reliance on RECELL, regulatory delays and cost controls would constrain progress and keep profitability uncertain.
What The Results Changed For AVITA Medical
AVITA Medical posted Q2 2026 revenue of US$21.702m, up from US$18.418m a year earlier, and the loss narrowed from US$9.92m to US$7.663m. Net margin moved from a loss of 53.9% to a loss of 35.3%. That shift lent some support to the optimistic case on revenue and efficiency, but profitability in absolute terms still did not meet either side's thesis.
The hinge assumption here was not just growth but the path toward durable earnings. When you test another healthcare stock, track whether rising sales are matched by a consistent improvement in net margin and progress toward breaking even, rather than treating top-line momentum alone as confirmation.
What AVITA Medical’s Surge Already Prices In
AVITA Medical now trades at US$15.18, far above the start-of-year level, and the selected Narrative’s Fair Value sits below the current price. The Narrative centers on broader hospital uptake of RECELL, Cohealyx and PermeaDerm, plus efficiency gains, as the engine for longer term earnings power.
A buyer at this level effectively leans on continued reimbursement stability and sustained adoption momentum. The key question is how the Narrative’s concerns about reimbursement setbacks, product concentration and funding needs might affect that confidence over time.
"Expanded reimbursement clarity and favorable clinical outcomes are boosting provider confidence, leading to broader hospital adoption and increased revenue opportunities. New product launches and operational efficiencies diversify market reach and support improved margins, positioning AVITA for long-term profitability."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
A Different Angle On AVITA Medical
Watching AVITA Medical can feel like tracking a broader healthcare puzzle. Skin repair and trauma care sit beside cancer drugs, surgeries and eye treatments.
Those parallel needs push hospitals toward therapies that tackle difficult conditions and streamline procedures. A large global group is investing heavily in medicines and devices shaped by those pressures.
It targets blood cancers and mental health, where treatment quality really matters. The same organisation promotes surgical robots and vision technologies positioned for premium procedures.
If AVITA Medical raises questions about specialised care, that wider push is worth noting. The identity behind this effort comes into focus next.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 20% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com